Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

08:10 EDT 22nd October 2017 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 8,300+

Relevant

Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 14062017] Prices from USD $350

Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions un...


NASH Contender Galectin Therapeutics Could Run Up Nicely - But Don't Stick Around

Galectin Therapeutics to Present at the Singular Research Summer Conference

NORCROSS, Ga., July 07, 2017 (GLOBE NEWSWIRE) Read more...


Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) Read more...

#news #biotech Study Details Interaction between Galectin-1 and Carbohydrate Ligands

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Study Details Interaction between Galectin-1 and Carbohydrate Ligands .A team of German researchers used advanced X-ray crystallography techniques to develop a structural understanding of the interaction between the… … Continue reading → Cet article #news #bi...

Galectin Therapeutics Inc GALT Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a d...

DSMB recommends continuation of Galectin's Phase IIb NASH trial

Intercept Runs Into Trouble; Other NASH Developers, Like Galectin, Gain Value

Autoimmune Disease Patent Granted To Galectin

  Life Sciences Jobs   ...

Patent For Reducing Inflammatory Response Granted To Galectin

  Life Sciences Jobs   ...

Galectin Therapeutics Inc GALT Medical Equipment Deals and Alliances Profile [Report Updated: 12072017] Prices from USD $250

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a d...

Galectin Announces Important Milestones Towards Completion Of NASH CX Trial

  Life Sciences Jobs   ...

Patent For Enhancing Immunotherapy In Cancer Treatment Granted To Galectin

  Life Sciences Jobs   ...

Galectin Reports 2017 Second Quarter Financial Results And Provides Business Update

  Life Sciences Jobs   ...

G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals

LEXINGTON, Mass., Sept. 14, 2017 /PRNewswire/ -- G3 Pharmaceuticals, a newly formed biopharmaceutical company located in Lexington, MA, today announced the start of its research and development program to pursue novel galectin-3 inhibitors.   Galectin-3 is a protein that is responsible for fibrosis forming in the heart and kidney, which impairs organ function, leading to heart failure, a...

Clarification: Galectin Reports 2017 Second Quarter Financial Results And Provides Business Update

  Life Sciences Jobs   ...

Galectin Receives Notice Of Chinese Allowance To Grant A Key Patent For Composition Of Matter For GR-MD-02

  Life Sciences Jobs   ...

Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017 [Updated: 20062017] Prices from

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017SummaryGalectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protei...

Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1) - Pipeline Review, H2 2017

LONDON, July 31, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5026449/SummaryGalectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) pipeline Target con...

Study Details Interaction between Galectin-1 and Carbohydrate Ligands

A team of German researchers used advanced X-ray crystallography techniques to develop a structural understanding of the interaction between the...

Immunotherapy efficacy up with Gal-1/SIT co-administration

(HealthDay)—Galectin-1 (Gal-1), allergen-specific immunotherapy (SIT) co-administration may suppress allergic responses in the intestine more than use of SIT or Gal-1 alone, according to an experimental study published online July 18 in Allergy.

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC. ...

Cancer detection with sugar molecules

Galectins are a family of proteins that have become a promising source of cancer research in recent years. A representative thereof is galectin-1. It sits on the surface of all human cells; on tumor cells, however, it occurs in enormous quantities. This makes it an interesting target for diagnostics and therapy.

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.


Quick Search
Advertisement
 

News Quicklinks